Switch to fixed-dose doravirine (100 mg) with islatravir (0·75 mg) once daily in virologically suppressed adults with HIV-1 on antiretroviral therapy: 48-week results of a phase 3, randomised, open-label, non-inferiority trial

作者：Jean‐Michel Molina, Giuliano Rizzardini, Catherine Orrell, Alejandro Afani, Alexandra Calmy, Shinichi Oka, Federico Hinestrosa, Princy Kumar, Pablo Tebas, Sharon Walmsley, Anjana Grandhi, Stephanie O. Klopfer, Isaias Noel Gendrano, Karen Eves, Todd Correll, Michelle C Fox, Jason Kim · 发表于：The Lancet HIV · 年份：2024 · DOI：10.1016/s2352-3018(24)00031-6 · 被引用次数：31 · 研究领域：HIV/AIDS drug development and treatment、HIV-related health complications and treatments、HIV Research and Treatment